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44Cushing’s syndrome is associated with increased mortality,
mainly due to cardiovascular complications, which are
sustained by the common development of systemic arterial
hypertension and metabolic syndrome, which partially
persist after the disease remission. Cardiovascular diseases
and hypertension associated with endogenous
hypercortisolism reveal underexplored peculiarities. The use
of exogenous corticosteroids also impacts on hypertension
and cardiovascular system, especially after prolonged
treatment. The mechanisms involved in the development
of hypertension differ, whether glucocorticoid excess is
acute or chronic, and the source endogenous or
exogenous, introducing inconsistencies among published
studies. The pleiotropic effects of glucocorticoids and the
overlap of the several regulatory mechanisms controlling
blood pressure suggest that a rigorous comparison of in-
vivo and in-vitro studies is necessary to draw reliable
conclusions. This review, developed during the first
‘Altogether to Beat Cushing’s syndrome’ workshop held in
Capri in 2012, evaluates the most important peculiarities
of hypertension associated with CS, with a particular focus
on its pathophysiology. A critical appraisal of most
significant animal and human studies is compared with a
systematic review of the few available clinical trials. A
special attention is dedicated to the description of the
clinical features and cardiovascular damage secondary to
glucocorticoid excess. On the basis of the consensus
reached during the workshop, a pathophysiology-oriented
therapeutic algorithm has been developed and it could
serve as a first attempt to rationalize the treatment of
hypertension in Cushing’s syndrome.
Keywords: antihypertensive treatment, blood pressure,
corticosteroids, Cushing’s syndrome, hypercortisolism,
hypertension, metabolic syndrome, vascular system
Abbreviations: 11b-HSD, 11beta-hydroxysteroid
dehydrogenase; ACCOMPLISH, Avoiding Cardiovascular
events through COMbination therapy in Patients LIving
with Systolic Hypertension; ACEi, angiotensin I-converting
enzyme inhibitor; ACTH, adreno-cortico-tropic hormone;
AMI, acute myocardial infarction; ANP, atrial natriuretic
peptide; ARB, angiotensin receptor blocker; BNP, brain
natriuretic peptide; BP, blood pressure; CD, Cushing’swww.jhypertension.comdisease; cGMP, cyclic guanosine 3’-5’ monophosphate; CS,
Cushing’s syndrome; DBP, diastolic blood pressure; ECS,
ectopic Cushing’s syndrome; EH, essential hypertension;
ENaC, epithelial sodium channel; eNOS, endothelial nitric
oxide synthase; EPO, erythropoietin; ET-1, endothelin-1;
HPA, hypothalamus–pituitary–adrenal axis; IMT, intima–
media thickness; IRS-1, insulin receptor substrate-1; LXR,
liver X receptor; PDE5, phosphodiesterase type 5; PI3-K,
phosphatidylinositol 3-kinase; PKB, protein kinase B; RAS,
renin–angiotensin system; SBP, systolic blood pressure;
UFC, urinary free cortisol; VEGF, vascular endothelial
growth factorINTRODUCTIONC
ushing’s syndrome, or chronic hypercortisolism, is a
severe endocrine disease due to the prolonged
exposure to glucocorticoid excess [1–3]. The
endogenous Cushing’s syndrome, caused by the endogen-
ous overproduction of cortisol by the adrenal glands, is
secondary to an adrenocorticotrophin (ACTH)-secreting
pituitary tumor [pituitary-dependent Cushing’s syndromeVolume 33  Number 1  January 2015
Hypertension in Cushing’s syndrome(CS) or Cushing’s disease (CD)] in around 70%, a cortisol-
secreting adrenal lesion (adrenal-dependent Cushing’s syn-
drome) in 15–20%, and an ACTH-secreting extra-pituitary
tumor [ectopic Cushing’s syndrome (ECS)] in 10–15% of the
cases [1–3]. The chronic administration of exogenous corti-
costeroids for different clinical conditions may induce the
development of an exogenous CS [1–3]. CS is associatedwith
a 2–5-fold increase in mortality compared to the general
population, mainly due to cardiovascular complications
[1–3]. CS is indeed characterizedby a peculiar clinical picture
complicated by several comorbidities, mainly including
systemic arterial hypertension, togetherwith visceral obesity,
impairment of glucose tolerance and dyslipidemia, config-
uring a metabolic syndrome [4–6]. However, the hyperten-
sion related toCS is not simply a component of the CS-related
metabolic syndrome. Indeed, CS-related hypertension dis-
plays several peculiarities, develops early and can persist
several years after clinical and hormonal remission of the
disease [4–6].
The hypothalamus–pituitary–adrenal axis (HPA), which
is responsible for the circadian rhythm of endogenous corti-
sol secretion, contributes to the circadian rhythm of blood
pressure (BP) [7,8], and HPA dysregulation has been
suggested as one of the factors involved in the pathogenesis
of essential hypertension (EH) [9,10]. Exogenous cortico-
steroids, which are prescribed to approximately 1% of the
adult population for various clinical conditions [11], signifi-
cantly affect this equilibrium [12,13], and are associated with
an increased risk of cardiovascular and cerebrovascular
diseases [14].
The ‘Altogether to Beat Cushing’s syndrome’ (ABC)
study group produced a systematic analysis of the
peculiarities of hypertension associated with endogenous
and exogenous CS, focusing on its controversial patho-
physiology and long-term clinical consequences. This nov-
el pathophysiology-oriented therapeutic approach enabled
a treatment-algorithm to be proposed during the first ABC
workshop held in Capri in 2012.
EPIDEMIOLOGYOF HYPERTENSION IN
CUSHING’S SYNDROME
Epidemiological data on hypertension associated with CS
are largely retrospective. However, the available data
suggested that 70–85% of adult patients [15,16] and
50–78% of pediatric patients [17–20] with endogenous
CS suffer from hypertension, compared to approximately
20% of patients long-term treated with exogenous cortico-
steroids [21,22]. A specific feature of hypertension associ-
ated with endogenous CS is the lack of a significant
difference in gender or among the different etiologies
of endogenous CS [15,16,23], as well as in the degree of
hypercortisolism, as BP values were found to be not
correlated with circulating cortisol levels [15,24,25]. Never-
theless, one study on pediatric patients with CS showed a
difference in the prevalence of systolic hypertension in
ACTH-independent (74%) and ACTH-dependent CS
(44%), despite an apparently similar degree of hypercortis-
olism, and demonstrated a positive correlation between BP
values and circulating cortisol levels [18]. Anyway, although
the prevalence of hypertension is similar among variousJournal of Hypertensionforms of endogenous CS, a tendency towards higher BP is
seen in adrenal compared to pituitary tumors. Figure 1
shows the BP values reported in the largest studies, accord-
ing to the different etiologies of CS. The duration of hyper-
cortisolism seems to be correlated with the development of
hypertension [15]; however, half of the pediatric patients
with CS, whose time to diagnosis is short, still develop
hypertension within a limited period of time [26,27].
PATHOGENESIS OF HYPERTENSION IN
CUSHING’S SYNDROME
The mechanisms involved in the development of hyper-
tension are complex and only partially understood. This
review summarizes the major data regarding the renin–
angiotensin system (RAS), the mineralocorticoid activity,
the sympathetic nervous system, and the vasoregulatory
system, together with indirect mechanisms, which con-
tribute to the development of CS-related hypertension
(Table 1). The mechanisms through which hypercortisolism
induces hypertension directly or indirectly, as well as the
mechanisms by which specific treatments, which could
counteract directly or indirectly the hypercortisolism-
induced changes that contribute to the CS-related hyper-
tension and consequent cardiovascular damage, are
discussed in this review, and reviewed in Fig. 2. The
pleiotropic effects of glucocorticoids and the several regu-
latory mechanisms controlling BP show significant overlap,
suggesting that a rigorous comparison of in-vivo and
in-vitro models is necessary to identify the relative contri-
bution of each component and draw reliable conclusions.
In addition, in most experimental settings, the acute effects
of glucocorticoids differ in many aspects from chronic
effects of either endogenous glucocorticoids or exogenous
corticosteroids. A systematic review of the mechanisms
involved in the pathogenesis of hypertension induced by
glucocorticoid excess in humans (Table 1) and animals
(Table 1S, http://links.lww.com/HJH/A423) is described
in this section of the review. This approach allowed the
appraisal of both the new pathways and the old paradigms.
Specific following sections of the review focus on the
clinical features and cardiovascular damage associated with
CS-related hypertension, and on the effect of treatment for
CS on hypertension. The review terminate with statements
on the pharmacological treatment of the hypertension
associated with CS, driven by the available knowledge.
These statements were the basis for the development of
a treatment algorithm for CS-related hypertension; this
proposed algorithm is displayed in Fig. 3.
The renin–angiotensin system
The RAS is the most extensively investigated system as a
putative contributor to hypertension in CS. Angiotensino-
gen is almost invariably increased [29], due to stimulation of
the hepatic synthesis, whereas renin may be suppressed, as
expected [30], or often normal [29], which is inappropriate
in view of the enhanced mineralocorticoid activity associ-
ated with CS. Circulating angiotensin II levels have been
reported to be normal [31], but the number of angiotensin II
receptors (type 1A) appears increased, and an enhanced
pressor response to angiotensin II infusion has beenwww.jhypertension.com 45
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FIGURE 1 The SBP (black) and DBP (white) values (mean SEM) are reported for some of the largest studies, according to the different causes of Cushing’s syndrome. The
gray boxes summarize the mean weighted pressure value for each group of studies; the black boxes summarize the overall effect for all groups.
Isidori et al.described in CS [32]. Confirmatory data on the involvement
of the angiotensin pathways come from the acute lowering
of BP obtained following oral administration of an angio-
tensin I-converting enzyme inhibitor (ACEi) in CS [29,33].
The fact that exogenous corticosteroids administration is
more frequently associated with suppressed renin, due
to a compensatory mechanism no longer observed inTABLE 1. Mechanisms involved in the pathogenesis of hypertension
Human studies
Renin–angiotensin system (RAS) " Angiotensinogen
" DBP in response to
" AT-II 1A receptor i
Mineralcorticoid activity " 11b-HSD 2 saturat
" Plasma volume
Sympathetic nervous system " Sensitivity to b rec
Vasoregulatory system " Endothelin 1 (ET-1
" Erythropoietin (EPO
" Circulating ANP
# ANP activity
# Nitric oxide pathwa
# Urinary PGE2
# of PGI2 production
# Urinary kallikrein
" Urinary kininase I,
11b-HSD 2,11b-Hydroxysteroid dehydrogenase type 2; Ang II, angiotensin II; ANP, atrial natriur
mineralcorticoid receptor; NEP, neutral endopepeptidase; PGE2, prostaglandin E2; PGI2 prostacy
46 www.jhypertension.comendogenous CS, where renin is often inappropriately nor-
mal, suggests that a long-standing hypercortisolism can
induce angiotensin receptor signaling dysregulation. The
clear evidence of the angiotensin pathway involvement in
the development of hypertension in CS suggests that this
should be the first pharmacological target. In fact, ACEi
have been successfully used to counteract hypertensiveinduced by glucocorticoid excess in human studies
Reference
[29,30,33]
peripheral administration of Ang II [29,33]
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Volume 33  Number 1  January 2015
S
ta
ti
ns
ox
yp
ur
in
ol
In
ha
le
d
 N
O
P
D
E
5-
in
hi
bi
to
rs
L
-a
rg
in
in
e
N
O
-d
on
or
d
E
nd
ot
he
lin
re
ce
pt
or
 
an
ta
go
ni
st
s
S
pi
ro
no
la
ct
on
e
ep
le
ro
no
ne
A
C
E
 in
hi
bi
to
rs
A
T-
R
 
an
ta
go
ni
st
s
C
on
tr
ac
ti
on
 p
ro
lif
er
at
io
n
R
el
ax
at
io
n
 a
nt
ip
ro
lif
er
at
io
n
C
ab
er
go
lin
e
P
as
ir
eo
ti
de
R
et
in
oi
c 
ac
id
β-
bl
oc
ke
rs
C
a2
+
-a
nt
ag
on
is
t
P
D
E
5-
in
hi
bi
to
rs
X
an
th
in
e
ox
id
as
e
is
G
C
P
D
E
5
cG
M
P
G
T
P
O
2
O
2–
L
-a
rg
in
in
e
V
C
A
M
-1
E
nd
ot
he
lin
-1
E
nd
ot
he
lin
re
ce
pt
or
E
nd
ot
he
liu
m
P
la
te
le
t
M
us
cu
la
rs
S
m
oo
th
 m
us
cl
e
ac
ti
va
ti
on
N
O
A
N
P
A
T
 I
A
T
E
T
C
N
P
sG
C
p
G
C
C
a2
+
†
cG
M
P
†e
N
O
S
L
-A
rg
N
O
P
T
N
P
B
N
P
A
E
T
B
E
T
B
E
TA
A
T
I
A
C
E
A
T
 II
E
T
A
D
P
T
hr
V
as
cu
la
r
re
m
od
el
lin
g
 
V
E
G
F
V
as
cu
la
r
sm
oo
th
-m
us
cl
e
ce
llsV
as
cu
la
r
en
do
th
el
iu
m
B
lo
od
pr
es
su
re
E
xt
ra
ce
llu
la
r
fl
ui
d
 v
ol
um
e
V
as
oc
on
st
ri
ct
io
n
of
 b
lo
od
 v
es
se
l
E
ff
ec
ti
ve
ci
rc
ul
at
in
g
vo
lu
m
e
E
T-
1
E
P
O
H
yp
ot
ha
la
m
us
C
R
H
P
it
ui
ta
ry
 g
la
nd
A
C
T
H
S
le
ep
 a
pn
ea
A
ng
io
te
ns
in
 II
A
ng
io
te
ns
in
 I
C
at
ec
ho
la
m
in
es
S
en
si
ti
vi
ty
 to
 β
-r
ec
ep
to
r
ag
on
is
ts
S
en
si
ti
vi
ty
 to
 s
el
ec
ti
v 
α
1-
ad
re
ne
rg
ic
re
ce
pt
or
 a
go
ni
st
s
β2
 a
dr
en
er
g
ic
 r
ec
ep
to
rsR
en
in
A
C
E
in
 lu
ng
s
In
su
lin
e
re
si
st
an
ce
H
2O
 e
cr
et
io
n
N
a+
  e
xc
re
ti
on
K
+
 e
xc
re
ti
on
D
iu
re
ti
cs
A
ng
io
te
ns
in
og
en
C
or
ti
so
l
A
dr
en
al
co
rt
ex
A
dr
en
al
 m
ed
ul
la
S
te
ro
id
og
en
es
is
In
hi
bi
to
rs
 a
nd
G
lu
co
co
rt
ic
oi
d
A
nt
ag
on
is
ts
K
et
oc
on
az
ol
e
M
et
yr
ap
on
e
M
it
ot
an
e
E
to
m
id
at
e
L
C
I6
99
M
if
ep
ri
st
on
e
In
su
lin
e
re
si
st
an
ce
G
ro
w
th
 f
ac
to
rs P
la
sm
a
m
em
br
an
e
L
-t
yp
e 
C
a2
+
ch
an
ne
l
C
a2
+
C
a2
+
C
a2
+ C
a2
+
C
a2
+
N
a+
N
a+
N
a+
K
+
N
a+
E
N
aC
C
l–
C
a2
+
P
P
P
P
P
P
H
D
A
C
H
D
A
C
N
uc
le
us
P
A
kt
A
kt
N
FA
T
N
FA
T
N
FA
T
β-
A
R
-a
go
ni
st
s
N
at
ri
ur
et
ic
pe
pt
id
es
A
N
P
N
O
N
K
X
2-
5
M
E
F
2
S
R
F
G
A
TA
4
P
I(
3)
K
-γ
G
S
K
3β
F
O
X
O
s
C
A
M
K
II
C
al
m
od
ul
in
C
al
m
od
ul
in
C
al
ci
ne
ur
in
A
tr
og
in
 1
A
K
A
P
1
R
C
A
N
1
P
K
G
P
D
E
5
S
ar
co
m
er
e
P
K
A
cG
M
P
cA
M
P
G
α
γ β
sG
C
p
G
C
A
C
D
N
A
 G
R
E
C
or
ti
so
l
C
or
ti
so
ne
N
A
D
11
βH
S
D
2
M
R
m
R
N
A
P
ro
te
in
s
E
xc
es
s 
co
rt
is
ol
 o
ve
rw
he
lm
es
 1
1B
H
S
D
2
A
ld
os
te
ro
ne
N
a/
K
-A
T
P
as
e
FI
G
U
R
E
2
Th
e
p
at
h
o
p
h
ys
io
lo
g
ic
al
m
ec
h
an
is
m
s
in
vo
lv
ed
in
th
e
d
ev
el
o
p
m
en
t
o
f
g
lu
co
co
rt
ic
o
id
-r
el
at
ed
h
yp
er
te
n
si
o
n
.
Th
e
sy
m
b
o
ls
",
#
an
d
$
re
p
re
se
n
t,
re
sp
ec
ti
ve
ly
,
an
in
cr
ea
se
,
d
ec
re
as
e
an
d
n
u
ll
ef
fe
ct
fo
r
ea
ch
o
f
th
e
af
fe
ct
ed
p
at
h
w
ay
,
o
n
th
e
b
as
is
o
f
th
e
st
u
d
ie
s
lis
te
d
in
Ta
b
le
1
an
d
Ta
b
le
1
S
(h
tt
p
:/
/li
n
ks
.lw
w
.c
o
m
/H
JH
/A
4
2
3
).
In
ca
p
s
b
lu
e
ar
e
h
ig
h
lig
h
te
d
th
e
d
ru
g
s
th
at
ca
n
b
e
u
se
d
to
co
u
n
te
ra
ct
th
e
p
at
h
w
ay
s
al
te
re
d
b
y
g
lu
co
co
rt
ic
o
id
ex
ce
ss
.
A
C
,
ad
en
yl
at
ec
yc
la
se
;
A
D
P,
ad
en
o
si
n
e
d
ip
h
o
sp
h
at
e;
A
K
A
P1
,
A
-k
in
as
e
an
ch
o
r
p
ro
te
in
1
;
A
T,
an
g
io
te
n
si
n
;
A
T
I,
an
g
io
te
n
si
n
ty
p
e
1
re
ce
p
to
r;
A
T-
R
an
ta
g
o
n
is
ts
,
an
g
io
te
n
si
n
re
ce
p
to
r
an
ta
g
o
n
is
ts
;
cA
M
P,
cy
cl
ic
ad
en
o
si
n
e-
m
o
n
o
p
h
o
sp
h
at
e;
C
M
K
II,
ca
lc
iu
m
-c
al
m
o
d
u
lin
-d
e
p
en
d
en
t
p
ro
te
in
ki
n
as
e
ty
p
e
2
;
C
N
P,
C
-t
yp
e
n
at
ri
u
re
ti
c
p
ep
ti
d
e;
C
R
H
,
co
rt
ic
o
tr
o
p
in
-r
el
ea
si
n
g
h
o
rm
o
n
e;
eN
O
S,
en
d
o
th
el
ia
l
n
it
ri
c
o
xi
d
e
sy
n
th
as
e;
ET
,
en
d
o
th
el
in
;
ET
A
,
en
d
o
th
el
in
re
ce
p
to
r
A
;
ET
B
,
en
d
o
th
el
in
re
ce
p
to
r
B
;
FO
X
O
s,
fo
rk
h
ea
d
h
o
m
eo
b
o
x
ty
p
e
O
tr
an
sc
ri
p
ti
o
n
fa
ct
o
rs
;
G
R
E
D
N
A
,
g
lu
co
co
rt
ic
o
id
re
sp
o
n
se
el
em
en
t-
D
N
A
;
G
SK
3
b
,
g
ly
co
g
en
sy
n
th
as
e
ki
n
as
e
3
B
et
a;
G
TP
,
g
u
an
o
si
n
e
tr
ip
h
o
sp
h
at
e;
H
D
A
C
,
h
is
to
n
e
d
ea
ce
ty
la
se
;
is
G
C
,
is
o
fo
rm
g
u
an
yl
at
ec
yc
la
se
;
L-
A
rg
,
L-
ar
g
in
in
e;
M
EF
2
,
m
yo
cy
te
en
h
an
ce
r
fa
ct
o
r-
2
;
M
R
,
m
in
er
al
co
rt
ic
o
id
re
ce
p
to
r;
N
A
D
,
n
ic
o
ti
n
am
id
e
ad
en
in
e
d
in
u
cl
eo
ti
d
e;
N
FA
T,
n
u
cl
ea
r
fa
ct
o
r
o
f
ac
ti
va
te
d
T
ce
lls
;
N
O
,
n
it
ri
c
o
xi
d
e;
N
P A
,
n
at
ri
u
re
ti
c
p
ep
ti
d
e
re
ce
p
to
r
ty
p
e
A
;
N
P
B
,
n
at
ri
u
re
ti
c
p
ep
ti
d
e
re
ce
p
to
r
ty
p
e
B
;
O
2
,
o
xy
g
en
;
O
2
- ,
su
p
er
o
xi
d
e
an
io
n
ra
d
ic
al
;
p
G
C
,
p
ar
ti
cu
la
te
g
u
an
yl
at
e
cy
cl
as
e;
PI
3
K
g
,
p
h
o
sp
h
at
id
yl
in
o
si
to
l
3
0 -
h
yd
ro
xy
ki
n
as
e;
PK
A
,
p
ro
te
in
ki
n
as
e
A
;
PK
G
,
cG
M
P-
d
ep
en
d
en
t
p
ro
te
in
ki
n
as
e;
R
C
A
N
1
,
re
g
u
la
to
r
o
f
ca
lc
in
eu
ri
n
1
p
ro
te
in
;
sG
C
,
so
lu
b
le
g
u
an
yl
at
ec
yc
la
se
;
SR
F,
se
ru
m
re
sp
o
n
se
fa
ct
o
r;
Th
r,
th
re
o
n
in
e;
V
C
A
M
-1
,
va
sc
u
la
r
ce
ll
ad
h
es
io
n
m
o
le
cu
le
1
.
Hypertension in Cushing’s syndromeJournal of Hypertension www.jhypertension.com 47
Start early use of
sartans or ACE-i
Start treatment for
hypercortisolemia
Yes
Yes
Yes
Yes
Yes
No
No
No
No
No
Hypokalemia?
Consider add-on
calcium antagonists
Rigorous BP control
achieved? (≤130/80)
Rigorous BP control
achieved? (≤130/80)
Rigorous BP control
achieved? (≤130/80)
Rigorous BP control
achieved? (≤130/80)
Consider add-on
α-blockers or nitric-
oxide donors
Cautious use of diuretics or β-blockers
(nephrolitiasis, concomitant use of hypoglycemic drugs)
Consider continuing treatment post-operatively
(sartans, ACE-i, nitric oxide pathway) to allow recovery of endothelial
dysfunction and improve reversal of cardiovascular remodeling
Consider early treatment for recurrence and/or cyclic disease
A
dopt all m
edical strateg
ies to
 im
prove hypercortisolism
 (dose-titration
/m
ultidrugs
C
onsider E
H
Add-on
spironolactone or
epleronone
FIGURE 3 Treatment algorithm based on a pathophysiological targets of glucocorticoid excess. ACEi, angiotensin-converting enzyme inhibitor; BP, blood pressure; EH,
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Isidori et al.effects of glucocorticoids [29,33], and given the enhanced
sensitivity of angiotensin receptors and the cardiovascular
remodeling frequently observed in CS, angiotensin recep-
tor blockers (ARBs) also appear a reasonable first choice in
the treatment algorithm (Fig. 3).
The mineralocorticoid activity
The mineralocorticoid activity has been traditionally con-
sidered a major player of hypertension secondary to glu-
cocorticoid excess. The mineralocorticoid receptor is a
nuclear receptor, mainly expressed at a renal level, which
is able to bind two different corticosteroids, aldosterone
and cortisol, with equal affinity [34]. Binding selectivity in
the renal cortex is guaranteed by 11beta-hydroxysteroid
dehydrogenase (11beta-HSD) type 2 (11beta-HSD2), which48 www.jhypertension.comcatalyzes the deactivation of cortisol to cortisone [35].
Severe CS is characterized by elevated cortisol levels that
overwhelm the ‘protective’ role of 11beta-HSD2, leading to
a functional mineralocorticoid excess, due to the binding
and activation of the mineralocorticoid receptor by exces-
sive glucocorticoids [36]. The mineralocorticoid receptor
hyperactivation at the renal level is known to induce
sodium retention and potassium excretion; this mechanism
could explain the development in patients with CS of both
hypertension, through sodium retention, and hypokalemia.
However, although most studies agree that 11beta-HSD2
saturation is the major mechanism for the development of
hypokalemia [37], its role in determining hypertension is
less evident. Some studies suggest that hypertension
induced by chronic hypercortisolism is not primarilyVolume 33  Number 1  January 2015
Hypertension in Cushing’s syndromemediated through sodium retention [38,39], which is instead
a feature of acute glucocorticoid excess [30]. In fact, chronic
hypercortisolism is associated with normal circulating
sodium and normal sodium excretion [30,40]. It is note-
worthy that another isoform of 11beta-HSD, the type-1
(11beta-HSD1), highly expressed in the liver and the adi-
pose tissue, and also in the heart, vascular endothelial and
smooth muscle cells, catalyzes the reactivation of cortisone
into cortisol, regulating local cortisol bioavailability,
and complicating the role of 11beta-HSD and the enhanced
mineralcorticoid activity in the development of CS-related
hypertension [35]. Moreover, beyond the mineralocorti-
coid receptor, glucocorticoid receptor also seems to play
a role in the renal regulation of sodium balance in patients
with CS. Indeed, both mineralocorticoid receptor and glu-
cocorticoid receptor have been thought to be responsible
for the enhanced epithelial sodium channel activation
(ENaC) and glomerular hyperfiltration, as the selective
blockade of mineralocorticoid receptor or glucocorticoid
receptor is insufficient to fully restore baseline conditions
[40]. This is consistent with clinical observations in CS
patients, whose BP improves more under mifepristone, a
selective glucocorticoid receptor antagonist [41], than under
spironolactone and epleronone, which are mineralocorti-
coid receptor antagonists [39,42]. In summary, renal min-
eralocorticoid receptor activation does not appear to be the
main determinant of hypertension in most patients with CS,
except in those with extremely elevated circulating cortisol
levels where renal mineralocorticoid receptor hyperactiva-
tion contributes to additional sodium and fluid retention,
beyond the increased excretion of potassium and conse-
quent hypokalemia. However, this does not exclude the
possibility that inappropriate vascular activation of miner-
alocorticoid receptor contributes to increased arterial wall
tension, even after mild chronic cortisol elevation. In
addition, a vascular mineralocorticoid receptor may exhibit
different kinetics, for instance, signal transduction might be
produced at different ligand concentrations from those
working in the kidney [43]. Indeed, mineralocorticoid
receptor blockade improves left ventricular hypertrophy
and failure in rats with low-aldosterone hypertension,
independently of BP-lowering, likely through an attenu-
ation of myocardial oxidative stress and coronary vascular
inflammation induced by glucocorticoid-activated minera-
locorticoid receptor [44]. In conclusion, renal mineralo-
corticoid receptor blockade with standard doses of
spironolactone or epleronone is a reasonable adjunctive
treatment in patients with hypokalemia (Fig. 3). Whether
higher doses are required to achieve an efficacious miner-
alocorticoid receptor blockade in the vasculature wall
remains to be established.
The sympathetic nervous system
The sympathetic nervous system, mediated by the catechol-
aminergic pathway, was traditionally considered an
important pathway in the development of CS-related hy-
pertension. However, only limited controlled data support
this evidence. In patients with CD, the concentrations of
catecholamines, including noradrenaline and adrena-
line, and adrenergic receptors seem unaltered [31],
as phenylethanolamine N-methyltransferase, the enzymeJournal of Hypertensionresponsible for noradrenaline to adrenaline methylation
[45]. An enhanced pressor response to adrenergic agonists
has been reported, but this evidence is controversial. In
patients with CD, noradrenaline [46] and the beta-adrener-
gic agonists isoprenaline and isoproterenol [31] elicited a
greater response than in normotensive patients. In contrast,
no difference in BP increase between CS patients and
control patients has been observed after infusions of the
selective alpha1-adrenergic receptor agonist phenyl-
ephrine [47]. Cardiac autonomic function was also inves-
tigated and found to be impaired in CS. A recent study
compared the responses of CS patients and healthy controls
to various autonomic tests, finding in the former a reduced
sympathetic reactivity [48]. The inconsistent findings and
the fact that most CS patients also develop diabetes, requir-
ing treatment with glucose-lowering drugs, suggest that
adrenergic blockade should not be a first-line treatment
for CS-related hypertension (Fig. 3). In addition, a rare, yet
described, contraindication to beta-blockers as a first-line
agent is represented by CS secondary to an ECS associated
with pheochromocytomas [37].
The vasoregulatory system
Many substances with vasoregulatory properties have been
reported to contribute to hypertension secondary to glu-
cocorticoid excess. Endothelin-1 (ET-1), a potent vasocon-
strictor, has been implicated in the pathogenesis of early
hypertension and premature atherosclerosis due to gluco-
corticoid excess [49]. To date, only one study has found an
increased ET-1 in patients with CS, although it was not
correlated with BP or cortisol excretion [50]. Interestingly, in
more than half of the patients, circulating ET-1 levels
remained elevated even after correction of hypercortisolism
[50], a finding attributed to persistent vascular damage.
Erythropoietin (EPO) mediates glucocorticoid-induced vas-
oconstriction in a dose-dependent manner, but this
phenomenon has been demonstrated only in healthy indi-
viduals acutely treated with exogenous corticosteroids [51],
but no proof exists of glucocorticoid regulation of EPO
gene expression. No data are presently available in
endogenous CS. Enhanced vascular responsiveness to var-
ious vasoconstrictors could be explained, at least in exper-
imental studies on murine aortic myocytes, through
glucocorticoid-induced down-regulation of the plasma
membrane sodium–calcium exchanger [52]. This mechan-
ism has been advocated as a rationale for the use of calcium
antagonists in the management of CS-related hypertension
(Fig. 3). Most studies on vasodilators have demonstrated the
detrimental effects of glucocorticoid excess on the nitric
oxide pathway through different mechanisms: inhibition of
nitric oxide synthase (NOS) expression [53,54], reduced
availability of substrates due to inhibition of the arginine
transporter, or impaired cofactor generation due to inhi-
bition of the tetrahydrobiopterin synthesis [55]. This is
confirmed by the low urinary nitric oxide metabolites
[54] and reduced plasma nitrate/nitrite ratio associated with
CS [56]. However, different studies demonstrated an
increase in endothelial NOS (eNOS) staining in subcu-
taneous small-resistance arteries of CS patients; this has
been interpreted as a paradoxical increase secondary to
enhanced oxidative stress [57]. A beneficial transientwww.jhypertension.com 49
Isidori et al.activation of cerebral eNOS has been reported to explain
the neuroprotective effects of glucocorticoid infusion after
stroke. This transient activation, apparently due to a non-
genomic glucocorticoid receptor action, is responsible for
increased regional cerebral blood flow [58]. The role of
cyclic guanosine 3
0
,5
0
-monophosphate (cGMP), a down-
stream target of nitric oxide signaling, remains unexplored
in CS. Its degradation is controlled by phosphodiesterase
type 5 (PDE5) and regulatedby steroid hormones [59] suchas
androgens, but data on glucocorticoids are missing. PDE5
inhibition could offer a potential treatment toprevent cardiac
remodeling associated with CS [60]. cGMP is a crucial second
messenger activated by G-coupled cardiac natriuretic pep-
tide receptors [atrial natriuretic peptide (ANP) and B-type
natriuretic peptide (BNP)]. ANP, a hormone with natriuretic
vasorelaxant and RAS-inhibiting properties, is often reported
as increased in CS [61–63]. Nevertheless, there is evidence
that ANP action is blunted in CS. Indeed, impaired cGMP
generation was described when physiological doses of ANP
were infused into patients with CD [64] or given to murine
renal vascular smooth muscle cells pretreated with dexa-
methasone [65]. This further finding, however, was not
confirmed in all studies [66]. CS might also be associated
with impaired production of other powerful vasodilators
including prostaglandins, prostacyclins and compounds of
the kallikrein–kinin system [29,67], the latter due to accel-
erated renal kininase activity [68].
The metabolic factor
A metabolic derangement is a common finding in CS; it is
manly characterized by an impairment of glucose and lipid
metabolism, together with a catabolic state, represented
by a generalized proteolysis. The effects of glucocorticoids
on glucose metabolism are complex and include: increase
of hepatic glucose production, reduction of glycogen syn-
thesis, decrease of insulin-dependent glucose uptake into
peripheral tissues, breakdown of proteins and lipids to
provide additional substrates for glucose production, and
inhibition of insulin release [69,70]. At hepatic level, glu-
cocorticoids not only antagonize metabolic actions of insu-
lin but also potentiate the effects of different hormones that
increase glucose levels, such as glucagon and adrenaline
[69,70]. The affected signaling pathways include the per-
oxisome proliferator-activated receptor-alpha (PPAR-
alpha) [71], and the nuclear liver X receptor (LXR) [72].
The peripheral effects of glucocorticoids are mainly exerted
at the level of skeletal muscle and visceral fat, where
glucocorticoids reduce glucose uptake by inhibiting the
expression and phosphorylation of insulin receptor sub-
strate-1 (IRS-1), phosphatidylinositol 3-kinase (PI3-K), and
protein kinase B (PKB)/Atk [69], all contributing to a
decrease in intracellular glucose uptake. A randomized
controlled trial in humans revealed that glucocorticoids,
even at low doses, can increase fasting plasma glucose and
insulin levels, and can decrease the ability of insulin to
suppress endogenous glucose production and lipolysis,
while increasing whole-body proteolysis [73].
The majority of patients with CS develops an overt
metabolic syndrome, where the impairment of glucose
tolerance and the dyslipidemia are associated with hyper-
tension, and are strictly dependent on the visceral adiposity50 www.jhypertension.comand insulin resistance, which are common features of the CS
[4]. A study on patients with CD clearly demonstrated that
circulating insulin levels were increased, suggesting a state
of insulin resistance, and that an increased waist-to-hip
ratio, which is a surrogate clinical marker of visceral adi-
posity, was significantly correlated with insulin levels and
the best predictor of the increase in carotid intima–media
thickness (IMT), an important preatherosclerotic lesion
[74]. These evidences suggested a direct link between
visceral adiposity, insulin resistance and premature athero-
sclerosis in CD [75]. In the long term, glucocorticoid excess
can impair insulin release from the pancreatic beta cells,
and this phenomenon is probably responsible for the
passage from a hyperinsulinemic impairment of glucose
tolerance to an overt diabetes mellitus in susceptible
patients who develop CS [76,77]. Noteworthy, metabolic
syndrome has been also documented in patients long-term
cured from CD [78]. It is noteworthy that the metabolic
derangements are likely important factors in the long-term
cardiovascular outcome, by accelerating atherosclerosis
and vasculature remodeling; however, in respect to the
etiology of hypertension, they are more likely facilitating
conditions.
The vascular factor
Vascular remodeling is a possible consequence of hyper-
tension due to glucocorticoid excess. Hypertrophic
changes in the morphology of small-resistance arteries
(increased media to lumen ratio, media thickness and wall
thickness) have been described in patients with CS [57].
Increased vascular endothelial growth factor (VEGF), a
potent angiogenic factor, has been reported to be respon-
sible for vasculature remodeling in various experimental
models of glucocorticoid excess [79]. Hyperinsulinemia,
impaired insulin signaling and insulin/IGF-I receptors
hybrid formation have been claimed to play a role in
vasculature smooth muscle cell dysfunction [80,81]. This
vascular remodeling and dysfunction may contribute to the
aggravation of hypertension associated with CS.
The sleep apnea
The obstructive sleep apnea syndrome (OSAS) is one of the
most common secondary conditions associated with resist-
ant hypertension, for which, however, a treatment is avail-
able [82]. One-third of the patients with CS develop OSAS
[83,84]. The sleep disturbances are strictly correlated with
the visceral obesity of patients with CD, making it unclear
whether it is primarily due to a direct effect of cortisol
excess or secondary to obesity. However, OSAS has been
described in lean patients with ECS [85], and CD patients
without OSAS exhibit an impaired sleep architecture, with
fragmented sleep and an abnormal pattern in rapid eye
movements, that resemble the sleep impairment of patients
with major depression [84]; these evidences suggest a direct
contribution of nocturnal hypercortisolemia. CS and OSAS
share the activation of sympathetic nervous system and
alterations of cortisol circadian rhythm [86]. Unfortunately,
the effects of continuous positive airway pressure (CPAP) in
lowering BP in unselected patients with OSAS turned out to
be below expectation [82,87]. More recently, it has been
shown that CPAP is mainly effective on nocturnal BP [87].Volume 33  Number 1  January 2015
Hypertension in Cushing’s syndromeTherefore, a treatment of OSAS with CPAP might be useful
in patients with CS, who do not have the physiological
decrease of BP during the night, namely the nondipper
hypertensive patients with CS.
CLINICAL FEATURES AND
CARDIOVASCULAR DAMAGE
ASSOCIATEDWITH HYPERTENSION IN
CUSHING’S SYNDROME
A near–linear relationship between hypertension and car-
diovascular, renal and neurological morbid and fatal
events has been repeatedly shown [88]. The relation-
ship between hypertension and cardiovascular mortality
is modified by the concomitance of other risk factors.
Metabolic syndrome and glucocorticoid excess are two
recognized important modifiers [89]. Hypertension is an
independent predictor of mortality in patients with CD
[90–92]. Most studies on CS failed to show a differential
elevation between SBP and DBP, while the loss of the
physiological nocturnal decrease [12] appears an early
feature of both endogenous and exogenous glucocorticoid
excess, with a high proportion of patients with nondipper
hypertension [7,8].
Hypertension in the different subtypes of
Cushing’s syndrome
The prevalence of hypertension appears similar among
various forms of endogenous CS; however, clinical and
pathophysiological differences characterize the subtypes of
CS. A tendency towards higher BP is seen in adrenal over
pituitary tumors associated with CS. This difference might
be related to the specific vasoactive effects of adrenal sex
steroids (androgens, estrogen and their metabolites), which
are generally suppressed in cortisol-secreting adrenal
tumors compared to pituitary tumors responsible for CD
[93,94]. Alternatively, it could be due to the retention of
some circadian rhythmicity of cortisol secretion in mild CD
that is lost in adrenal tumors responsible for adrenal-
dependent CS. However, even in CD, over half of the
patients do not present nocturnal BP-dipping, showing a
lower than 10% fall in SBP and DBP at night and abnormal
heart rate values [8]. Zacharieva et al. [95] compared the
circadian BP of 100 patients with CS (80 CD and 20 adrenal
CS), with 40 patients with EH, and found the blunting of
nocturnal decline more severe in patients with adrenal
disease. The nocturnal drop in heart rate was preserved
in both groups, suggesting that the main effect was on
vascular tone. In ECS, more frequently than in other sub-
types of CS, patients develop severe hypokalemia, mainly
due to saturation of the activity of the 11beta-HSD2. The
rapidity and severity of onset of hypercortisolism in this
condition is responsible for a severe organ damage [37]. A
rarely recognized form of familial CS, with an insidious
onset, has been recently identified [96]. Assie et al. [96]
described 33 patients with ACTH-independent macronod-
ular hyperplasia, most with ARMC5 mutations. Few studies
describing the characteristics of hypertension in this genetic
form of CS are available [96,97]; interestingly, whereas
hypercortisolism is the most frequent reason for clinicalJournal of Hypertensionpresentation in families with bilateral macronodular adre-
nal hyperplasia positive for ARMC5 mutations, hyperaldos-
teronism is unusually prominent in those negative for
ARMC5 mutations [97]. Future studies of the genotype–
phenotype relationships in familial CS may provide an
opportunity to study the very early stages of CS develop-
ment. Completely different is the hypertension associated
with exogenous glucocorticoid that affects about 20% of
patients receiving prolonged treatment with corticoste-
roids. In these cases, the clinical picture is determined by
the dose, route of administration, duration and type of
steroid used [98].
Cardiac damage
CS is associated with an increased mortality from multi-
system risk that is already elevated several years before
the diagnosis, confirming that is caused by cortisol excess.
Compared to matched controls, patients with active disease
have a hazard ratio of 6.0 (2.1–17.1) for heart failure and of
2.1 (0.5–8.6) for acute myocardial infarction (AMI). An
increased prevalence of left ventricular hypertrophy and
concentric remodeling are consistently found in CS [99].
Muiesan et al. [99] also described important left ventricular
functional alterations, such as a decrease in left ventricular
systolic performancemeasuredat themid-wall, and a change
in diastolic filling with an abnormal relaxation pattern. Toja
et al. [100] found that CS patients presented a more severe
change in left ventricular mass index and relative wall thick-
ness than both normotensive and matched hypertensive
controls. No clinically relevant diastolic dysfunction was
seen in patients or controls with normal BP [100], suggesting
that hypertension was involved, albeit not the only factor, in
the whole range of cardiac alterations observed in CS. The
most important ultrastructural abnormality in CS cardiomy-
opathy is myocardial fibrosis. This seems directly related to
cortisol action rather than to cardiac hypertrophy or BP,
exerted through an enhanced responsiveness to angiotensin
II [101]. Activation of the mineralocorticoid receptor and
glucocorticoid receptor also contributes to its development.
It was recently shown that glucocorticoids activate cardiac
mineralocorticoid receptor during experimental myocardial
infarction [102], supporting the use of mineralocorticoid
receptor antagonists. Yiu et al. [103] demonstrated that
myocardial fibrosis is significantly increased in untreated
CS compared to EH, and partly reversible after successful
treatment of CS. On ECG, CD patients show prolonged QT
and features of left ventricular hypertrophy, even if the
association of CD with a prolonged QT seems to be inde-
pendent of other risk factors, including hypertension. This
suggests a cardiotoxic effect of hypercortisolism per se [104].
Moreover, in comparison with patients matched for similar
cardiovascular risk factors, CS patients show a sympathova-
gal imbalance, characterized by relatively increased para-
sympathetic activity. It is still unknown whether this acts to
counterbalance cortisol-induced effects on BP, and cardiac
structure and function or has a different pathophysiological
significance [105]. Hypertensive CS patients show impair-
ment in all parasympathetic function parameters. The sig-
nificantly different expiratory-to-inspiratory ratio might be
explained by the effect of hypertension or antihypertensive
medications in some patients [48].www.jhypertension.com 51
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The IMT of both the carotid and aortic arteries is signifi-
cantly increased in CS patients and associated with prema-
ture development of carotid atherosclerotic plaques
[75,106]. Compared to matched controls, patients with
active disease have a hazard ratio of 4.5 (1.8–11.1) of
having a stroke [92]. Successful treatment of glucocorticoid
excess decreases carotid artery IMT, which, however,
remains above matched controls, respectively, 1 [74] and
5 [78] years after the cure. In untreated patients, IMT is
closely correlated to central adiposity and insulin resist-
ance, suggesting a causative link that, however, is lost after
the cure, claiming into cause additional factors such as
persistence of hypertension or inflammation [74,78].
Vasculature remodeling: small vessels
Cushing’s syndrome is also associated with endothelial dys-
function, which precedes the development of atherosclero-
sis [4,74,107]. CS is associated with altered brachial flow-
mediated vasodilation [108]. Endothelial dysfunction is
associated with impaired microvascular reactivity, which
seems to be modulated by hypertension [109], and
with vascular smooth cell hypertrophy and wall fibrosis of
small arteries [57]. These effects are probably due to miner-
alocorticoid pro-inflammatory actions. CS patients also show
structural abnormalities in the resistance arteries, as indicated
by an increased media-to-lumen ratio. These abnormalities
arecharacterizedbyhypertrophic remodeling rather than the
eutrophic remodeling usually observed in patients with EH
which seems to be the consequence of cortisol growth-
stimulating properties and/or vascular oxidative stress [57].
However, glucocorticoids may also activate the mineralo-
corticoid receptor in vascular smooth muscle cells, which
involves mitogen-activated protein kinases/extracellular sig-
nal-regulated kinases (MAPK/ERK)-dependent pathways
[110]. All these data suggest that glucocorticoids contribute
to cardiovascular remodeling via mineralocorticoid receptor
signaling, independently of sodium retention or circulating
aldosterone [111].
Neither renal nor retinal damage inducedbyhypertension
have been adequately investigated in CS patients. It has been
found that more than 80% of CS patients have increased
urinary albumin excretion. In general, renal proteinuria may
be caused by increased glomerular filtration rate, resulting
from higher intraglomerular pressure, damage to the glo-
merular barrier or decreased tubular reabsorption. Urinary
albumin excretion is positively correlatedwith SBP andDBP,
and fasting plasma glucose, suggesting that these factors may
have contributed to the increased albumin excretion. How-
ever, it is also possible that hypercortisolemia itself increases
urinary albumin excretion, although the mechanism is not
clear yet [112]. An increased excretion rate of some amino
acids, including cysteine, has been documented in patients
with active CD, but not in cured patients [113], suggesting a
specific effect of glucocorticoid excess on renal function.
Renal effects of glucocorticoid also includes calcium metab-
olism that is responsible for hypercalciuria, increasedurinary
oxalate and ultimately to nephrolithiasis, a common feature
of active CS [114]. Further studies are necessary to investigate
both renal and retinal damage secondary to hypertension in
CS patients.52 www.jhypertension.comEFFECTOF TREATMENTOFCUSHING’S
SYNDROMEON HYPERTENSION
The definitive therapy of CS-related hypertension is the
surgical removal of the tumor responsible for the disease.
However, medical therapy is gaining a broader spectrum of
applications [115], not only in preparation for surgery or
recurrences, due to the recent development of new agents
with proven efficacy in lowering ACTH secretion from
pituitary tumors and antisteroidal drugs to counteract glu-
cocorticoid excess. Interestingly, mortality data show that
adequate control of hypercortisolemia does not always
result in a normalization of BP. Some studies reveal a
normalization of the increased cardiovascular risk after
immediate surgical cure of CD [116,117], whereas others
did not [90–92]. Interestingly, studies with longer follow-up
tend to show a persistently elevated risk that is specific for
AMI and stroke, but not for heart failure [92]. Among all CS
patients, men, those with diabetes or hypertension have a
significantly higher mortality risk [3].
Effect of surgical treatment
Transsphenoidal resection of pituitary tumor for CD pro-
vides a long-term cure in more than 70% of the cases
[2,3,19,115]. After 5 years of cortisol normalization, how-
ever, hypertension was found in 40% of the patients,
notably higher than would be expected in a sex and
age-matched population [74,78]. Bilateral adrenalectomy
is recommended for inoperable or occult sources of CS.
A large Mayo Clinic cohort found that bilateral adrenalec-
tomy resolved hypertension in 64% of the patients, which is
a higher improvement rate than seen with parameters such
as diabetes and obesity, confirming the strict association of
high BP with glucocorticoid excess [118]. Magiakou et al.
[25] evaluated 31 children with CS of different etiologies
before and 1 year after surgery: 93.5% had preoperative
systolic hypertension that persisted after surgical treatment
in 30.7, 15.8 and 5.5% of patients at 3, 6 and 12 months,
respectively. DBP completely normalized in all patients
within 3 months [25]. In contrast, after successful treatment
of 23 children with CS, an Italian study found a persistent
significant impairment in arterial distensibility and altered
24-h BP monitoring, compared to controls [119]. This
suggests that while BP improves faster in young patients,
who are somewhat protected from microvascular damage,
an increased cardiovascular risk persists despite cortisol
and BP normalization. Recent mortality data reveal that
increased hypertension can be found after 30 years of
follow-up [92], independently of surgical removal of the
cause of CS. The risk appears as a consequence of the
length of exposure to glucocorticoid excess, with an
increased mortality found in patients with symptoms lasting
for more than 3 years prior to surgery, compared to those
with less than a 3-year history [3].
Effect of medical therapy
Medical therapy of endogenous glucocorticoid excess
includes agents that modulate pituitary or ectopic ACTH
release (somatostatin analogs, dopamine agonists), inhibit
steroidogenesis (ketoconazole, metyrapone, mitotane, eto-
midate) or block the glucocorticoid receptor (mifepristone)Volume 33  Number 1  January 2015
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54 www.jhypertension.com[120]. Several studies which evaluated the effectiveness of
these drugs on the control of hypercortisolism in patients
with CS also analyzed the effect on clinical feature, includ-
ing BP and hypertension. Table 2 described the outcome of
recent registered clinical trials in patients with CS, detailing
the effects of these compounds on BP and hypertension.
Ketoconazole, an inhibitor of 17-alpha hydroxilase and
17,20 lyase activity, improved BP in over 80% of the cases
[120]. Metyrapone, an inhibitor of 11-beta-hydroxylase
activity, with a good response in urinary free cortisol
(UFC) levels [122], is, however, associated with a potential
rise in intermediates with mineralocorticoid activity, thus
potentially worsening hypertension, as well as hypokale-
mia. Mitotane has been widely used in patients with adre-
nocortical carcinoma, but also in severe cases of CS, as an
alternative to bilateral adrenalectomy. In particular, in ECS,
UFC levels were normalized in 91% of the patients, leading
to improved BP in 63% of the hypertensive patients, who
were able to stop or reduce antihypertensive drugs [123].
Various novel agents have been evaluated for their possible
inhibition of ACTH secretion, including the dopamine
agonist cabergoline and most recently somatostatin analog
pasireotide; both cabergoline and pasireotide have been
demonstrated to significantly improve hypertension associ-
ated with CD [124,125]. In particular, in two different multi-
center prospective clinical trial, pasiretotide was able to
improve SBP and DBP by 6 and 4 mmHg, respectively,
when administered alone [126], and by 12 and 8mmHg,
respectively, when administered in combination with
cabergoline and ketoconazole [127]. The new compound
LCI699, an orally active inhibitor of the 11-beta-hydroxyl-
ase, is being investigated in CS [128]. However, similar to
metyrapone, the inhibition of 11-beta-hydroxylase activity
increases cortisol and aldosterone precursors with miner-
alcorticoid activity, and could induce hypokalemia and
worsen hypertension. The experience with mifepristone,
a glucocorticoid receptor antagonist, is limited; BP was
reduced in about half of the patients, although in some
patients, hypertension and hypokaliemia worsened, requir-
ing co-treatment with spironolactone [129]. In a recent
multicenter, prospective, open-label study, mifepristone
induced improvement in BP in a significant number of
patients with CS; in particular, DBP was improved in
38% of the patients displaying only hypertension, whereas
DBP and/or antihypertensive treatment was decreased in
more 52% of the patients displaying hypertension alone or
in association with disturbances of glucose metabolism
[130]. However, despite the treatment with mifepristone,
in most cases, additional antihypertensive agents were also
necessary. In summary, hypertension can be difficult to
control without normalization of hypercortisolemia, but
this is often insufficient, suggesting the need for an inte-
grated pharmacologic approach [131].
TREATMENTOF HYPERTENSION IN
CUSHING’S SYNDROME
Table 2S (http://links.lww.com/HJH/A423) presents a sys-
tematic review of studies investigating the pharmacological
treatment of hypertension in CS patients, as well as the
effects of medical or surgical therapy of CS on hypertension.Volume 33  Number 1  January 2015
Hypertension in Cushing’s syndromeThis enabled a number of clinical considerations to be
drawn that have been integrated with the pharmacology
statements driven by experimental data to build the treat-
ment algorithm presented in Fig. 3. First, clinical control of
hypertension has been considered difficult in the presence
of sustained long-standing hypercortisolism. Therefore, it is
reasonable that the primary medical goal in most studies
has been to control glucocorticoid excess. However, given
that treatment is often surgical and the response not always
successful at the first attempt, a reasonable position would
be to use add-on antihypertensives to prevent cardiovas-
cular complications. Although the prevalence of hyperten-
sion is high in CS patients, less than 50% are actually treated
for hypertension prior to surgery, especially if they are
young patients [19,91]. This discrepancy may be related
to the evidence that, unless BP is extremely high, once the
etiology of CS is established, most physicians wait for
surgical cure or relay on antisteroids rather than commenc-
ing early antihypertensive treatment. This approach seems
driven by empirical reasoning rather than evidence-based
medicine, as the few available studies exploring the effects
of antihypertensives showed consistent, reproducible
effects. A different scenario is when the syndrome is not
yet recognized, and the patients, especially when older, are
inadequately treated for an EH. Second, use of add-on
antihypertensives is supported by data on end-organ com-
plications that seem to occur earlier and at lower BP values
in CS than in EH. Such accelerated vascular remodeling and
atherosclerosis should prompt aggressive treatment. Third,
studies show that the antihypertensive drug is often
selected according to generic guidelines for the manage-
ment of EH rather than pathophysiological considerations
relative to CS. This could also explain the discrepancy in
results: some studies found no improvement in BP, whereas
in others, even a single antihypertensive drug was effective.
The proposed treatment algorithm (Fig. 3) is based on a
step-up approach with different drugs specifically targeting
the pathways most commonly affected by glucocorticoid
excess. Fourth, persistence of hypertension after treatment
of CS deserves special attention. An aggressive approach,
such as with lipid-lowering drugs following ischemic heart
attack, could be advocated for the treatment of residual
hypertension following resolution of the glucocorticoid
excess. Fifth, little attention has been paid to the impaired
endothelial function, in particular, on the nitric oxide path-
way, despite solid pathophysiological data and promising
preliminary results. On the basis of the recent publications
showing both early diastolic impairment and blunted
natriuretic peptide signaling in hypercortisolism and the
antiremodeling effects of chronic PDE5i in diabetic cardi-
omyopathy, CS patients may be excellent candidates for a
dedicated study on chronic PDE5i to revert cardiovascular
remodeling. Similarly, the effect of lifestyle interventions
and physical activity on the outcome of CS after treatment
has not been studied. Considering that myopathy and
obesity both reduce the mobility of these patients, specific
guidelines are needed to aid physicians in choosing a
suitable rehabilitation program. Finally, the results of the
recent multicenter, randomized controlled clinical trials
exploring the effects of pasireotide [126] and LCI699 [128]
or mifrepistone [130] allow a more precise estimate of howJournal of Hypertensionmuch BP is likely to drop following effective control of
hypercortisolemia. However, these drugs have a complex
mechanism of action that focuses mainly on the control of
hypercortisolism. Hence, it cannot be ruled out that the
effects on BP may be due to a combination of many
different factors. These recent studies have shown that
hypercortisolism control is very effective in lowering both
systolic and diastolic pressure. Therefore, whereas the old
retrospective, heterogeneous studies reviewed herein
suggested that control of hypercortisolemia was insufficient
to prevent end-organ disease, this may not necessarily
apply to the more recent, well controlled trials, in which
stricter remission/cure criteria are applied. However, even
in the latest studies, only about 50% of the patients were
able to discontinue antihypertensives completely. Given
the data on the presence of significant cardiovascular
comorbidities even after complete remission, prompt and
aggressive control of BP remains desirable.
Proposed algorithm for the treatment of
Cushing’s syndrome-related hypertension
The European guidelines for the management of hyperten-
sion recommend to lower BP with drugs, even when
hypertension is in the grade 1 range, if total cardiovascular
risk is high because of diabetes, cardiac or kidney disease
[89,132]. The data, herein presented, clearly show that CS
represents a condition of increased risk deserving pharma-
cological treatment. Furthermore, although lifestyle modi-
fications are recommended for CS patients, especially
dietary control of metabolic syndrome [133], some other
interventions, such as physical exercise and weight control,
are more difficult in patients with CS, due to myopathy and
generalized pain, which often characterize the disease.
Recent guidelines indicate that diuretics, beta-blockers,
calcium antagonists, ACEis and ARBs are all suitable for
the initiation and maintenance of antihypertensive treat-
ment, either as monotherapy or in some combinations [89].
However, given the pathophysiological peculiarities of CS,
integrated with the recent recommendations [89], the ABC
study group formulated a treatment algorithm that is specifi-
cally tailored for the management of CS-related hyperten-
sion (Fig. 3). This algorithm includes as a first-line treatment
the use of any of the two blockers of the RAS, ACEi or ARB,
in light of the many evidences supporting a major alteration
of this pathway in CS, and for their cardioprotective effects.
Conversely, beta-blockers are not considered a first-line
drug, in part, because they are not superior, or even slightly
worse, than calcium antagonists in reducing total mortality,
cardiovascular events and stroke, but also for the possible
contraindications, represented by metabolic syndrome,
glucose intolerance and sleep apnea, all very frequent in
patients with active CS or after the cure [134]. Calcium
antagonists are powerful in lowering BP and do not present
specific contraindications in respect to CS; they also have a
greater efficacy than diuretics and beta-blockers in delaying
atherosclerosis and IMT of the carotid artery [135] and
preventing stroke [136]. Among diuretics, spironolactone
should be used to control hypokalemia, when present, and
has been found to have beneficial effects in heart failure
[137], and, although never tested in randomized controlled
studies on hypertension, can be used as a third-line drug towww.jhypertension.com 55
Isidori et al.lower BP. Eplerenone could be used as an alternative to
spironolactone, especially in men [138]; however, it is not
available as a subsidized medication in several countries, it
is expensive compared to amiloride and spironolactone
and, therefore, could suffer compliance in medium to long-
term treatment. Thiazides should be used cautiously for the
risk of aggravating hypokalemia, which is very common in
CS, hyperuricemia, gout and diabetes, which may occur in
CS [139,140]. Hydrochlorothiazide has been used for pre-
vention of calcium-containing kidney stones, a frequent
complication of CS, because at high dose, it can reduce
urinary calcium excretion [139,140]; however, thiazides also
reduce free water clearance and recent evidences ques-
tioned their use for kidney stone prevention [141,142].
Aliskiren, a direct inhibitor of renin at the site of its acti-
vation, has never been tested in CS; it can have possible
complications in patients with diabetes and cannot be
combined with any other drug acting on RAS. For these
reasons it should not be a first choice. The alpha-blocker
doxazosin has effectively been used as third-line therapy in
the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)
[143] and does not offer specific contraindications related to
CS. Monotherapy is seldom sufficient to control BP in CS;
however, no controlled studies on combination therapies
are available in this group of patients. In non-CS patients,
the Avoiding Cardiovascular events through COMbination
therapy in Patients LIving with Systolic Hypertension [414]
trial documented the positive synergy an ACEi–calcium
antagonist combination. This combination was superior
to the combination of beta-blocker and diuretics in reduc-
ing cardiovascular events [144] that appeared to elicit more
cases of new-onset diabetes in susceptible individuals,
compared with other combinations [145]. Agents acting
at different levels of the RAS should never be combined.
New BP-lowering drugs (nitric oxide donors, vasopressin
antagonists, neutral endopeptidase inhibitors, aldosterone
synthase inhibitors, etc.) are all undergoing early stages of
investigation [128,146].
In summary, the most appropriate approach to treat
hypertension and related cardiovascular damage in patients
with CS seems to commence with an ACEi or an ARB, if
necessary, coupled with calcium-antagonists and/or a min-
eralocorticoid receptor antagonist, depending on the
severity of the condition and the presence of hypokalemia.
Use of other diuretics, alpha-blockers and, eventually, beta-
blockers should be limited to selected cases after appro-
priate dose-titration of other agents taking into account the
possible contraindications related to the state of hyper-
cortisolemia.
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Reviewer 2
This ambitious review of an important subject would
have benefitted by addressing each of the various
aetiologies of Cushing’s separately. They differ widely
in clinical and laboratory presentation, natural history,
pathophysiology and appropriate treatment. Treatment
priorities will also be different for each unique patient,
rejecting a formalised approach. Hopefully, this review
may assist choices of antihypertensive agents. The
exciting recent contributions from genetics to the
understanding of familial forms deserve great attention
and emphasis, promising early identification of those60 www.jhypertension.comat risk from this often insidious and late-diagnosed
condition, and better understanding of pathophysio-
logy.Reviewer 3
The different causes of Cushing’s syndrome with the attend-
ant diversity of the pathophysiological mechanisms under-
lying the rise of blood pressure make it difficult to provide
definitive guidelines for antihypertensive treatment in
these patients. However, a careful and thorough evaluation
of the present knowledge has allowed the authors to
provide some major therapeutic recommendations, some
of which of definite clinical relevance.Volume 33  Number 1  January 2015
